Investing

FDA Rejects Genetech (DNA) Cancer Drug, Shares Off 9%

According to the WSJ and other source, the FDA has rejected Genetech’s (DNA) drug Avastin as a breast cancer treatment. Shares are off 9% on the news

Douglas A. McIntyre

 

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.